Electra Therapeutics PAO reports 187K stock options
Electra Therapeutics, Inc. (ETRA) had its Principal Accounting Officer, Parry Graham, file an initial statement of beneficial ownership reporting two employee stock options over its common stock.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) had its Principal Accounting Officer, Parry Graham, file an initial statement of beneficial ownership reporting two employee stock options over its common stock. One option covers 114,000 shares at an exercise price of $4.96 per share, expiring on April 8, 2036, and is early exercisable with vesting beginning one year after March 30, 2026. A second option covers 73,402 shares at an exercise price of $15.00 per share, expiring on September 16, 2036, with monthly vesting commencing on September 17, 2026. No purchases or sales of common stock are reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Parry Graham
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 187,402 contracts (Direct)
Footnotes (2)
- F1. 1/4th of the total shares subject to this option vested one year after March 30, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F2. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.
Key Figures
Option shares at $4.96: 114,000 shares
Exercise price (first option): $4.96 per share
Expiration date (first option): April 8, 2036
+5 more
8 metrics
Option shares at $4.96
114,000 shares
Employee stock option over common stock at a $4.96 exercise price, expiring April 8, 2036
Exercise price (first option)
$4.96 per share
Employee stock option for 114,000 underlying shares of common stock
Expiration date (first option)
April 8, 2036
Expiry of the 114,000-share employee stock option
Option shares at $15.00
73,402 shares
Employee stock option over common stock at a $15.00 exercise price, expiring September 16, 2036
Exercise price (second option)
$15.00 per share
Employee stock option for 73,402 underlying shares of common stock
Expiration date (second option)
September 16, 2036
Expiry of the 73,402-share employee stock option
Vesting start (first option)
March 30, 2027
One quarter of the 114,000-share option vests one year after March 30, 2026
Vesting commencement (second option)
September 17, 2026
Monthly vesting of the 73,402-share option begins on this date
Key Terms
early exercisable, right of repurchase, vest, Principal Accounting Officer
4 terms
early exercisable financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase"
right of repurchase financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase"
vest financial
"1/4th of the total shares subject to this option vested one year after March 30, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Principal Accounting Officer financial
"Parry Graham serves as Principal Accounting Officer of Electra Therapeutics, Inc."
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Electra Therapeutics (ETRA) disclose in this Form 3 for Parry Graham?
The filing reports that Parry Graham, Principal Accounting Officer of Electra Therapeutics, holds two employee stock options over the company’s common stock, detailing their share amounts, exercise prices, expiration dates, and vesting schedules. It does not report any purchases or sales of shares.
What are the exercise prices of the Electra Therapeutics (ETRA) options reported by Parry Graham?
One employee stock option has an exercise price of $4.96 per share and the other has an exercise price of $15.00 per share. Both options relate to common stock of Electra Therapeutics and are reported as directly owned derivative securities.
What vesting schedules apply to Parry Graham’s Electra Therapeutics (ETRA) option grants?
For the 114,000-share option, one quarter vests one year after March 30, 2026, then 1/48 vests monthly. For the 73,402-share option, 1/48 of the shares vests monthly commencing from September 17, 2026, as described in the footnotes.
When do Parry Graham’s Electra Therapeutics (ETRA) stock options expire?
The option over 114,000 shares at a $4.96 exercise price expires on April 8, 2036. The option over 73,402 shares at a $15.00 exercise price expires on September 16, 2036, according to the reported derivative holdings.
Are Parry Graham’s Electra Therapeutics (ETRA) options early exercisable or subject to repurchase?
The footnote states that the 114,000-share option is early exercisable, subject to the issuer’s right of repurchase. The 73,402-share option is described with a monthly vesting schedule but without the early-exercise and repurchase language.
Does this Electra Therapeutics (ETRA) Form 3 indicate trades under a Rule 10b5-1 plan?
No. The filing describes option holdings and vesting terms for Parry Graham but does not state that any transactions were made pursuant to a Rule 10b5-1 trading plan, and it reports no open-market purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
